Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04457845 in Adults With Tourette Syndrome
NCT02134080Phase 1Terminated
- Sponsor
- Yale University
- Start
- May 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Tourette syndrome (TS) comparing PF-04457845 with Placebo (2 arms). Primary endpoint: Improvement in Tic Severity at 12 weeks. Started May 2014; status: terminated.
02
Drugs
JZP-150
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT02134080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134080.